-
Mashup Score: 15
A bamlanivimab study showed a 72% reduction in the incidence of COVID-19 and an 80% reduction of progression in the virus in residents in assisted living facilities and nursing staff.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 16An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19 - 3 year(s) ago
This Medical Letter review summarizes the evidence underlying the US Food and Drug Administration’s emergency use authorization of bamlanivimab, an investigational neutralizing IgG1 monoclonal antibody for treatment of COVID-19, including specification of high-risk patient groups eligible for the…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#Bamlanivimab, an IV MAb, has @US_FDA EUA status based on its association w a reduction in ED visits & hospitalizations in recently dx'd pts w mild-mod #COVID19 at high risk of progression to severe disease https://t.co/ETsCcjnCoa @MedicalLetter
-
-
Mashup Score: 3COVID-19 Guideline, Part 1: Treatment and Management - 3 year(s) ago
COVID-19 is a pandemic with a rapidly increasing incidence of infections and deaths. Many pharmacologic therapies are being used or considered for treatment. Given the rapidity of emerging literature, IDSA felt the need to develop living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and…
Source: www.idsociety.orgCategories: Infectious Disease, Latest HeadlinesTweet-
Among ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests #bamlanivimab/#etesevimab rather than no bamlanivimab/etesevimab. For evidence appraisal & rationale, visit https://t.co/isitU1Tcs3.
-
IDSA has released a new guideline recommendation on the use of #bamlanivimab/#etesevimab among ambulatory patients for the Treatment & Management of Patients with COVID-19. 📄: https://t.co/isitU1Tcs3 #COVID19Guidelines https://t.co/2dDfJYk0vE
-
-
Mashup Score: 1
Read the Panel’s statement on the FDA Emergency Use Authorization for bamlanivimab plus etesevimab for the treatment of COVID-19.
Source: COVID-19 Treatment GuidelinesCategories: Infectious Disease, Latest HeadlinesTweet-
New recommendations from the @NIH on the #EUA of #Bamlanivimab and #Etesevimab combination against #COVID19 https://t.co/Zrr2AeA8K0
-
-
Mashup Score: 3FDA OKs Antibody Combo for Milder COVID-19 - 3 year(s) ago
Cut hospitalizations, deaths in patients at high risk of severe disease
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Two monoclonal antibodies administered together, #bamlanivimab and #etesevimab, received emergency use authorization for mild to moderate #COVID19 patients at risk of severe disease. By @mms_walker, @MedPageID. https://t.co/B9bvozCbnW
-
-
Mashup Score: 2
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
The U.S. FDA) granted Emergency Use Authorization (EUA) for #bamlanivimab (LY-CoV555) 700 mg & #etesevimab (LY-CoV016) 1400 mg together to treat recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19 https://t.co/L1skqjem6Z https://t.co/rt3cnYrLld
-
-
Mashup Score: 25COVID-19 Guideline, Part 1: Treatment and Management - 3 year(s) ago
COVID-19 is a pandemic with a rapidly increasing incidence of infections and deaths. Many pharmacologic therapies are being used or considered for treatment. Given the rapidity of emerging literature, IDSA felt the need to develop living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and…
Source: www.idsociety.orgCategories: Infectious Disease, Latest HeadlinesTweet-
IDSA has released new guideline recommendations on the use of #bamlanivimab among hospitalized patients and #casirivimab/#imdevimab among ambulatory patients for the Treatment & Management of Patients with COVID-19. #COVID19Guidelines 📄https://t.co/SK6zyOJKtO https://t.co/jxE6rLy67l
-
-
Mashup Score: 2
Positive results were announced from a phase 3 trial evaluating bamlanivimab for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff of long-term care facilities.
Source: Pulmonology AdvisorCategories: Latest Headlines, PulmonologyTweet-
Positive results were announced from a phase 3 trial evaluating #bamlanivimab, a potent neutralizing IgG1 #monoclonalantibody, for the prevention of #SARS-CoV-2 infection and #COVID-19 in residents and staff of #long-term care facilities. Read More: https://t.co/PGobcPKSso
-
-
Mashup Score: 1
Investigators tested bamlanivimab monotherapy as well as in combination with etesevimab.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
The combination therapy group showed a statistically significant difference. #Bamlanivimab and #Etesevimab https://t.co/7QuhWSNYfM
-
-
Mashup Score: 18
Investigators tested bamlanivimab monotherapy as well as in combination with etesevimab.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#Bamlanivimab combination therapy with #etesevimab can reduce the viral load of #COVID19 by Day 11 https://t.co/7QuhWSwnoe
-
A #bamlanivimab study showed a 72% reduction in the incidence of #COVID19 and an 80% reduction of progression in the virus in residents in assisted living facilities and nursing staff. https://t.co/OsuQQUkyvM